

SUPPORT C™ DCB in De Novo lesions: Interim Preliminary Result¹



STUDY DESIGN



Single-arm, prospective, all-comers multicentre registry



154 patients across 2 sites



Median follow-up of 6 months

PATIENT CHARACTERISTICS

61%
ACS

35%
DIABETES

11%
CKD

COMPLEX LESION CHARACTERISTICS

60%
TYPE B2-C

15%
BIFURCATION

3%
CTO

21%
LONG
DIFFUSE

8%
SEVERE
CALCIFICATION

9%
OSTIAL
DISEASE

CLINICAL OUTCOMES

95.5%
MACE-FREE²

98%
FINAL TIMI 3
FLOW

1.9%
CLINICAL-DRIVEN
TVR

0
BAIL-OUT STENTS
AFTER DCB

SUPPORT C™ DCB demonstrated strong 6-month outcomes in the all-comers, high-risk patients with 95.5% MACE-free² survival, no bail-out stenting, no device-related deaths, and low TVR rates.

¹Clinical Data presented in MYLIVE 2026.

²MACE-free was defined as freedom from Cardiac Death, Target Vessel MI and Clinically Driven TVR.